Clinical Scorecard: Patient-Reported Costs of Chronic Urticaria in Portugal: A Study of Its Economic Impact

At a Glance

Key Highlights

• After weighting for population severity distribution, estimated annual societal cost was €4,687 per patient.
• Presenteeism accounted for 62% of estimated societal costs.
• Patients covered 64% of direct costs themselves.
• Among employed patients, each one-point increase in DLQI was associated with €270 in annual productivity loss, independent of disease severity.
• National estimates were described as indicative because prevalence is uncertain and sample representativeness is limited.

Guideline-Based Recommendations

Diagnosis

• The article defines CU as recurrent wheals, angioedema, or both continuing for more than 6 weeks.
• The study population comprised adults reporting a physician-established diagnosis from a dermatologist or allergologist/immunologist; the excerpt does not state whether diagnoses were independently re-verified.

Management

• The article states that second-generation H1 antihistamines are first-line treatment, with dose escalation advised before proceeding further.
• The article identifies omalizumab as the subsequent treatment for CSU unresponsive to antihistamines.

Monitoring & Follow-up

• The study assessed health-related quality of life using the Dermatology Life Quality Index (DLQI).
• The study examined productivity loss among employed patients in relation to DLQI and disease severity.

Risks

• The article describes CU-related interference with sleep, occupational activity, and social functioning.
• The authors state that national estimates are indicative because prevalence is uncertain and sample representativeness is limited.

Patient & Prescribing Data

Adults aged 18 years or older living in Portugal who reported a physician-established CU diagnosis from a dermatologist or allergologist/immunologist.

The article describes second-generation H1 antihistamines as first-line treatment, dose escalation before further treatment, and omalizumab as the subsequent treatment for antihistamine-unresponsive CSU. The study reports that patients bore 64% of direct costs.

Clinical Best Practices

Related Resources & Content